Search
Immix Biopharma Inc
IMMXAdd to Watchlist
12.500USD
-0.220-1.73%
Close 09-18 16:00（ET）
891.33MMarket Cap
LossP/E TTM
More Details of Immix Biopharma Inc Company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc Profile
Ticker SymbolIMMX
Company nameImmix Biopharma Inc
IPO dateDec 16, 2021
CEORachman (Ilya)
Number of employees18
Security typeOrdinary Share
Fiscal year-endDec 16
Address11400 West Olympic Blvd.
CityLOS ANGELES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code90064
Phone18889581084
Websitehttps://immixbio.com/
Ticker SymbolIMMX
IPO dateDec 16, 2021
CEORachman (Ilya)
Company Executives of Immix Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
72.34K
+8.64%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
6.25K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.87M
+0.13%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
925.13K
+0.68%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
181.00K
+3.45%
FAQs
Who are the top five shareholders of Immix Biopharma Inc?
The top five shareholders of Immix Biopharma Inc are: Mr. Jason Hsu, Ph.D.
How many institutions hold shares of Immix Biopharma Inc (IMMX)?
As of 2026Q1, 105 institutions hold shares of Immix Biopharma Inc, with a combined market value of approximately 24.89M, accounting for 45.75% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 18028804.00.